Literature DB >> 25391246

Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in rheumatoid arthritis patients.

S Mokuda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25391246     DOI： 10.1007/s00198-014-2958-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  3 in total

Review 1.  Osteoporosis in inflammatory joint diseases.

Authors:  C Roux
Journal:  Osteoporos Int       Date:  2010-06-15       Impact factor: 4.507

2.  Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.

Authors:  K Ebina; J Hashimoto; K Shi; M Kashii; M Hirao; H Yoshikawa
Journal:  Osteoporos Int       Date:  2014-08-01       Impact factor: 4.507

3.  Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs.

Authors:  S Mokuda; N Sawada; K Matoba; A Yamada; M Onishi; Y Okuda; K Jouyama; Y Murata; K Takasugi
Journal:  J Endocrinol Invest       Date:  2012-10       Impact factor: 4.256
  3 in total
  1 in total

1.  Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda.

Authors:  K Ebina; J Hashimoto; K Shi; M Kashii; M Hirao; H Yoshikawa
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.